Orgenesis Inc. | Balance Sheet

Fiscal year is December-November. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
50.80
1,314.10
4,168.00
891.00
3,519.00
16,456
Total Accounts Receivable
24.10
889.50
2,619.00
2,135.00
2,210.00
11,192
Inventories
-
-
301.00
400.00
725.00
1,736
Other Current Assets
22.80
26.00
1,118.00
779.00
841.00
913
Total Current Assets
97.70
2,229.50
8,206.00
4,205.00
7,295.00
30,297
Net Property, Plant & Equipment
12.90
13.00
4,296.00
4,573.00
5,104.00
11,901
Total Investments and Advances
-
-
5.00
-
1,660.00
1,007
Intangible Assets
-
-
26,188.00
24,634.00
25,735.00
31,865
Other Assets
3.60
6.40
53.00
75.00
78.00
377
Total Assets
114.20
2,249.00
38,748.00
33,487.00
39,872.00
75,447
ST Debt & Current Portion LT Debt
264.10
2,451.50
7,739.00
5,491.00
3,158.00
Accounts Payable
-
-
3,475.00
4,554.00
3,914.00
Other Current Liabilities
722.40
2,211.90
5,262.00
4,455.00
9,842.00
Total Current Liabilities
986.40
4,663.30
16,476.00
14,500.00
16,914.00
Long-Term Debt
-
-
2,540.00
4,350.00
4,533.00
Provision for Risks & Charges
4.30
5.00
5.00
5.00
6.00
Deferred Taxes
-
-
3,327.00
1,862.00
690.00
Other Liabilities
1,158.00
560.00
1,382.00
273.00
-
Total Liabilities
2,148.60
5,228.20
23,730.00
20,990.00
22,143.00
Common Equity (Total)
2,034.40
2,979.30
6,440.00
12,497.00
14,123.00
Total Shareholders' Equity
2,034.40
2,979.30
15,018.00
12,497.00
14,123.00
Total Equity
2,034.40
2,979.30
15,018.00
12,497.00
17,729.00
Liabilities & Shareholders' Equity
114.20
2,249.00
38,748.00
33,487.00
39,872.00
Accumulated Minority Interest
-
-
-
-
3,606.00
Preferred Stock (Carrying Value)
-
-
21,458.00
-
-

About Orgenesis

View Profile
Address
20271 Goldenrod Lane
Germantown Maryland 20876
United States
Employees -
Website http://www.orgenesis.com
Updated 07/08/2019
Orgenesis, Inc. engages in the cell therapy development and manufacturing for advanced medicinal products. It focuses on developing novel and proprietary cell therapy trans-differentiation technologies for the treatment of diabetes. It operates through the Contract Development and Manufacturing Organization (CDMO), and Cellular Therapy Business (CT) segments.